{"filing":{"accession_number":"0001447028-26-000024","cik":"0001447028","ticker":"ABUS","company_name":"Arbutus Biopharma Corp","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"abus-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/abus-20260526.htm"},"events":[{"id":8817,"run_id":7739,"accession_number":"0001447028-26-000024","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Arbutus Biopharma held its Annual Meeting of Shareholders on May 26, 2026, with voting results on four proposals: director elections, approval of the 2026 Omnibus Share and Incentive Plan, an advisory vote on named executive officer compensation, and appointment of Ernst \u0026 Young LLP as independent auditor.","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2021,"accession_number":"0001447028-26-000024","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of the 2026 Omnibus Share and Incentive Plan, which authorizes issuance of 16.3 million common shares for compensatory purposes. This is a material compensation plan amendment affecting equity incentive arrangements for directors and officers, fitting the exec_compensation category. The plan replaces prior equity plans and requires shareholder approval, making it a significant governance and compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:00.955875+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2022,"accession_number":"0001447028-26-000024","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Arbutus Biopharma's May 26, 2026 Annual Meeting, covering four proposals: director elections, approval of the 2026 Omnibus Share and Incentive Plan, advisory vote on named executive officer compensation, and appointment of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:00.955875+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2021,"accession_number":"0001447028-26-000024","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of the 2026 Omnibus Share and Incentive Plan, which authorizes issuance of 16.3 million common shares for compensatory purposes. This is a material compensation plan amendment affecting equity incentive arrangements for directors and officers, fitting the exec_compensation category. The plan replaces prior equity plans and requires shareholder approval, making it a significant governance and compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:00.955875+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-05-27"},{"id":2022,"accession_number":"0001447028-26-000024","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Arbutus Biopharma's May 26, 2026 Annual Meeting, covering four proposals: director elections, approval of the 2026 Omnibus Share and Incentive Plan, advisory vote on named executive officer compensation, and appointment of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:00.955875+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-05-27"}]}